MIR506

Summary

MIR506 (microRNA 506, HGNC:32143) is a microRNA gene on chromosome Xq27.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 574511 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32143
Approved symbol	MIR506
Name	microRNA 506
Location	Xq27.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-506
Ensembl gene	ENSG00000207731
Ensembl biotype	miRNA
OMIM	300877
Entrez	574511
RNAcentral	URS000075DF7E — ncRNA, 124 nt, 3 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384998

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384998 — 1 exons

Exon	Start	End
ENSE00001500005	147230720	147230843

Expression profiles

Bgee: expression breadth broad, 29 present calls, max score 77.27.

Top tissues by expression

29 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adult mammalian kidney	UBERON:0000082	77.27	gold quality
blood	UBERON:0000178	73.74	gold quality
tibial artery	UBERON:0007610	72.51	gold quality
gastrocnemius	UBERON:0001388	71.95	gold quality
lower esophagus muscularis layer	UBERON:0035833	70.95	gold quality
substantia nigra	UBERON:0002038	69.32	gold quality
colon	UBERON:0001155	69.13	gold quality
myometrium	UBERON:0001296	68.41	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	68.05	gold quality
right atrium auricular region	UBERON:0006631	67.69	gold quality
intestine	UBERON:0000160	67.54	gold quality
body of stomach	UBERON:0001161	66.86	gold quality
metanephros cortex	UBERON:0010533	66.35	gold quality
skin of abdomen	UBERON:0001416	66.07	gold quality
transverse colon	UBERON:0001157	65.84	gold quality
liver	UBERON:0002107	65.47	gold quality
left ovary	UBERON:0002119	64.22	gold quality
esophagus mucosa	UBERON:0002469	64.17	gold quality
putamen	UBERON:0001874	62.16	gold quality
small intestine Peyer’s patch	UBERON:0003454	61.42	gold quality
brain	UBERON:0000955	61.30	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	60.58	gold quality
cerebellar hemisphere	UBERON:0002245	59.94	gold quality
spleen	UBERON:0002106	59.64	gold quality
right lobe of liver	UBERON:0001114	58.70	gold quality
hypothalamus	UBERON:0001898	57.38	gold quality
corpus callosum	UBERON:0002336	52.88	silver quality
left testis	UBERON:0004533	45.96	gold quality
testis	UBERON:0000473	45.31	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.33

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• investigation into role of MIR506 as an anti-oncogene: expression of MIR506 is reduced in transformed malignant cells compared to normal bronchial epithelial cells; MIR506 seems to negatively regulate expression of N-Ras gene in lung cancer cells (PMID:21726609)
• miR-506 is up-regulated in primary biliary cirrhosis, binds the 3’UTR region of AE2 mRNA, and prevents protein translation, leading to diminished AE2 activity and impaired biliary secretory functions. (PMID:22383162)
• Loss of miR-506 is associated with ovarian cancer. (PMID:23410973)
• concluded that miR-506 plays a key role in the process of EMT through posttranslational control of EMT-related genes (PMID:23717581)
• we demonstrated that miR-506 mimics inhibited tumorigenesis in vivo, implicating that miR-506 might be a potential therapeutic molecule for selective killing of lung cancer cells (PMID:24469051)
• CDK4 and CDK6 are direct targets of miR-506, and miR-506 can inhibit CDK4/6-FOXM1 signalling, which is activated in the majority of serous ovarian carcinomas. (PMID:24604117)
• This newly identified miR-506/Gli3 axis provides further insight into the pathogenesis of cervical cancer and indicates a potential novel therapeutic agent for the treatment of cervical cancer. (PMID:24608427)
• YAP mRNA might be one of the targets of miR-506. (PMID:25087998)
• miR-506 represents a new class of miRNA that regulates both E-cadherin and vimentin/N-cadherin in the suppression of epithelial-to-mesenchymal transition and metastasis (PMID:25230372)
• miR-506 is a regulator of InsP3R3 expression and InsP3R3-mediated Ca2+ signaling and secretion (PMID:25378392)
• Low miR-506 expression was significantly correlated with Gastric Cancer. (PMID:25707493)
• our study demonstrates that miR-506 may act as a tumor suppressor in gastric cancer(GC) and that the miR-506/Yap1 axis may help us better understand the molecular mechanisms of GC progression. (PMID:25846731)
• MiR-506 sensitized cells to DNA damage through directly targeting the double-strand DNA damage repair gene RAD51. MiR-506 is a robust clinical marker for chemotherapy response and survival in serous ovarian cancers. (PMID:25995442)
• MiR-506 Over-Expression Inhibits Proliferation and Metastasis of Breast Cancer Cells. (PMID:26059632)
• MicroRNA506 participates in pancreatic cancer pathogenesis by targeting PIM3 (PMID:26238203)
• miR-506 was identified as an ETS1 targeting suppressor of metastatic invasion and angiogenesis in gastric cancer (PMID:26362716)
• the present study is the first to provide evidence that miR-506 acts as a tumor suppressor, at least partially, by directly downregulating IQGAP1 in breast cancer cells. (PMID:26398880)
• miR-506-EZH2 axis inhibits colon tumor cell proliferation and metastasis by activating/suppressing specific downstream tumor-associated genes and the Wnt/beta-catenin signaling pathway. (PMID:26452129)
• findings collectively suggest that miR-506 acts as a tumor suppressor via regulation of ROCK1 expression and may thus be a promising therapeutic target for HCC (PMID:26474697)
• MiR-506 suppresses the angiogenesis of liver cancer by inhibiting SPHK1. (PMID:26549227)
• miR-506 significantly decreased the expression and transcription activity CREB1 to inhibit esophageal squamous carcinoma cell proliferation. (PMID:26617801)
• The miR-506/FOXQ1 axis plays an important role in the pathogenesis of cervical cancer. (PMID:26935526)
• we identified sphingosine kinase 1 (SPHK1) as a novel target of miR-506, the expression of which inhibited the SPHK1/Akt/NF-kappaB signaling pathway, which is activated in pancreatic cancer. High SPHK1 expression was significantly associated with poor survival in a large cohort of pancreatic cancer specimens. (PMID:27065335)
• Kaplan-Meier analysis showed that patients with high miRNA-506 expression had significantly shorter survival time than those with low miRNA-506 expression. (PMID:27345473)
• MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression. (PMID:27371108)
• analysis of the diverse roles and underlying mechanisms of miR-506 and its involvement in cancer; there is a potential therapeutic strategy based on miR-506 [review] (PMID:27542202)
• Bioinformatics analysis and luciferase reporter assay revealed that NEAT1 directly bound to the miR-506-3p, which has been reported to act as a tumor suppressor in diverse cancers. the tumor-promoting effects of NEAT1 in pancreatic cancer cells is at least partly through negative modulation of miR-506-3p. (PMID:27888106)
• our combined results elucidated genetic and epigenetic silencing of miR-506-3p enhances COTL1 oncogene expression to foster NSCLC progression. (PMID:27893417)
• miR-506 acts as a tumor suppressor and inhibits malignancy of colorectal cancer cells through directly targeting LAMC1. (PMID:27993882)
• These findings expand the known mechanisms of MIR506-mediated tumor suppression to activation of autophagy-related cell death and suggest a strategy for using MIR506 as an anti-STAT3 approach to Pancreatic ductal adenocarcinoma treatment. (PMID:28121485)
• elevated expression of miR-506 and miR-4316 in peripheral blood were potential molecular markers for early colorectal cancer. (PMID:28405738)
• The present study found that the KLF4 and KLF5 3’-UTR contains one conserved target site of miR-506 and miR-124, and the overexpression of miR-506 and miR-124 inhibited the H2O2-induced upregulation of KLF4 and KLF5 in HCMs. (PMID:28849090)
• Different proinflammatory cytokines enhance the expression of miR-506 in biliary epithelial cells; miR-506 induces primary biliary cholangitis-like features in cholangiocytes and promotes immune activation, representing a potential therapeutic target for primary biliary cholangitis patients (PMID:28922472)
• These data indicate a process of NF-kappaB-induced miR-506 suppression and JAG1 upregulation upon IL-1beta induction. (PMID:28926924)
• miR-506 has an important role in suppressing cervical cancer cell proliferation and suppresses the expression of ABCC4 by directly targeting its 3’-UTR (PMID:29788724)
• NEAT1, stabilized by LIN28B, promoted HGSOC progression by sponging miR-506. (PMID:30154460)
• An inverse correlation between the miR5063p and YAP1 mRNA levels was detected in lung adenocarcinoma specimens. (PMID:30535506)
• miR-506 functions as a tumor suppressor miRNA and plays a significant role in inhibiting human mantle cell lymphoma cell proliferation and metastasis by suppressing B7H3 expression. (PMID:30553455)
• miR-506 enhanced natural killer cell cytotoxicity against hepatocellular carcinoma cells by targeting STAT3. (PMID:30554487)
• alterations induced by miR-506-3p mimics were partly reversed by SPHK1 overexpression or treatment of rapamycin (PMID:30669957)

Cross-species orthologs

0 orthologs

Paralogs (9): MIR514A2 (ENSG00000207866), MIR514A3 (ENSG00000207867), MIR514A1 (ENSG00000207868), MIR513B (ENSG00000207871), MIR507 (ENSG00000207969), MIR513A2 (ENSG00000207984), MIR509-1 (ENSG00000208000), MIR509-3 (ENSG00000212014), MIR514B (ENSG00000252583)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.